These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27611116)

  • 1. Emotional eating and in vivo norepinephrine transporter availability in obesity: A [
    Bresch A; Rullmann M; Luthardt J; Becker GA; Reissig G; Patt M; Ding YS; Hilbert A; Sabri O; Hesse S
    Int J Eat Disord; 2017 Feb; 50(2):152-156. PubMed ID: 27611116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[(11)C]O-methylreboxetine.
    Li CS; Potenza MN; Lee DE; Planeta B; Gallezot JD; Labaree D; Henry S; Nabulsi N; Sinha R; Ding YS; Carson RE; Neumeister A
    Neuroimage; 2014 Feb; 86():306-10. PubMed ID: 24121204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hunger and disinhibition but not cognitive restraint are associated with central norepinephrine transporter availability.
    Bresch A; Rullmann M; Luthardt J; Becker GA; Patt M; Ding YS; Hilbert A; Sabri O; Hesse S
    Appetite; 2017 Oct; 117():270-274. PubMed ID: 28647385
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships of in vivo brain norepinephrine transporter and age, BMI, and gender.
    Koohsari S; Sadabad FE; Pittman B; Gallezot JD; Carson RE; van Dyck CH; Li CR; Potenza MN; Matuskey D
    Synapse; 2023 Sep; 77(5):e22279. PubMed ID: 37382240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of posttraumatic stress disorder with reduced in vivo norepinephrine transporter availability in the locus coeruleus.
    Pietrzak RH; Gallezot JD; Ding YS; Henry S; Potenza MN; Southwick SM; Krystal JH; Carson RE; Neumeister A
    JAMA Psychiatry; 2013 Nov; 70(11):1199-1205. PubMed ID: 24048210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[(11)C]O-methylreboxetine and HRRT.
    Ding YS; Singhal T; Planeta-Wilson B; Gallezot JD; Nabulsi N; Labaree D; Ropchan J; Henry S; Williams W; Carson RE; Neumeister A; Malison RT
    Synapse; 2010 Jan; 64(1):30-8. PubMed ID: 19728366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imaging human brown adipose tissue under room temperature conditions with (11)C-MRB, a selective norepinephrine transporter PET ligand.
    Hwang JJ; Yeckel CW; Gallezot JD; Aguiar RB; Ersahin D; Gao H; Kapinos M; Nabulsi N; Huang Y; Cheng D; Carson RE; Sherwin R; Ding YS
    Metabolism; 2015 Jun; 64(6):747-55. PubMed ID: 25798999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The central nervous norepinephrine network links a diminished sense of emotional well-being to an increased body weight.
    Melasch J; Rullmann M; Hilbert A; Luthardt J; Becker GA; Patt M; Villringer A; Arelin K; Meyer PM; Lobsien D; Ding YS; Müller K; Sabri O; Hesse S; Pleger B
    Int J Obes (Lond); 2016 May; 40(5):779-87. PubMed ID: 26620766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [
    Sanchez-Rangel E; Gallezot JD; Yeckel CW; Lam W; Belfort-DeAguiar R; Chen MK; Carson RE; Sherwin R; Hwang JJ
    Int J Obes (Lond); 2020 Apr; 44(4):964-967. PubMed ID: 31636373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adult attention-deficit/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[
    Ulke C; Rullmann M; Huang J; Luthardt J; Becker GA; Patt M; Meyer PM; Tiepolt S; Hesse S; Sabri O; Strauß M
    Transl Psychiatry; 2019 Nov; 9(1):301. PubMed ID: 31732713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noradrenaline transporter availability on [
    Vettermann FJ; Rullmann M; Becker GA; Luthardt J; Zientek F; Patt M; Meyer PM; McLeod A; Brendel M; Blüher M; Stumvoll M; Hilbert A; Ding YS; Sabri O; Hesse S
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(9):1618-1625. PubMed ID: 29627935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress.
    Logan J; Wang GJ; Telang F; Fowler JS; Alexoff D; Zabroski J; Jayne M; Hubbard B; King P; Carter P; Shea C; Xu Y; Muench L; Schlyer D; Learned-Coughlin S; Cosson V; Volkow ND; Ding YS
    Nucl Med Biol; 2007 Aug; 34(6):667-79. PubMed ID: 17707807
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central noradrenaline transporter availability in highly obese, non-depressed individuals.
    Hesse S; Becker GA; Rullmann M; Bresch A; Luthardt J; Hankir MK; Zientek F; Reißig G; Patt M; Arelin K; Lobsien D; Müller U; Baldofski S; Meyer PM; Blüher M; Fasshauer M; Fenske WK; Stumvoll M; Hilbert A; Ding YS; Sabri O
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):1056-1064. PubMed ID: 28066877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET Quantification of the Norepinephrine Transporter in Human Brain with (
    Moriguchi S; Kimura Y; Ichise M; Arakawa R; Takano H; Seki C; Ikoma Y; Takahata K; Nagashima T; Yamada M; Mimura M; Suhara T
    J Nucl Med; 2017 Jul; 58(7):1140-1145. PubMed ID: 27980046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine.
    Ding YS; Lin KS; Logan J; Benveniste H; Carter P
    J Neurochem; 2005 Jul; 94(2):337-51. PubMed ID: 15998285
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs.
    Ding YS; Lin KS; Garza V; Carter P; Alexoff D; Logan J; Shea C; Xu Y; King P
    Synapse; 2003 Dec; 50(4):345-52. PubMed ID: 14556239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantitative analysis of norepinephrine transporter in the human brain using PET with (S,S)-18F-FMeNER-D2.
    Arakawa R; Okumura M; Ito H; Seki C; Takahashi H; Takano H; Nakao R; Suzuki K; Okubo Y; Halldin C; Suhara T
    J Nucl Med; 2008 Aug; 49(8):1270-6. PubMed ID: 18632811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modeling and analysis of PET studies with norepinephrine transporter ligands: the search for a reference region.
    Logan J; Ding YS; Lin KS; Pareto D; Fowler J; Biegon A
    Nucl Med Biol; 2005 Jul; 32(5):531-42. PubMed ID: 15982584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo assessment of [11C]MRB as a prospective PET ligand for imaging the norepinephrine transporter.
    Severance AJ; Milak MS; Kumar JSD; Prabhakaran J; Majo VJ; Simpson NR; Van Heertum RL; Arango V; Mann JJ; Parsey RV
    Eur J Nucl Med Mol Imaging; 2007 May; 34(5):688-693. PubMed ID: 17180600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Compartmental modeling of [(11)C]MENET binding to the norepinephrine transporter in the healthy human brain.
    Adhikarla V; Zeng F; Votaw JR; Goodman MM; Nye JA
    Nucl Med Biol; 2016 May; 43(5):318-23. PubMed ID: 27150035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.